Bio-Bridge Science Announces the Appointment of Mitchell Kronenberg, Ph.D. to its Scientific Advisory Board

  
    
  
  
    
      Bio-Bridge Science, Inc. (OTCBB:BGES), a biotechnology company engaged 
      in the commercial development of vaccines for the prevention and 
      treatment of human infectious diseases, announced the appointment of Dr. 
      Mitchell Kronenberg to the Scientific Advisory Board of the Company. Dr. 
      Kronenberg is an internationally recognized leading expert on NKT cells 
      and mucosal immunology. He has over 230 highly cited publications, is 
      currently on the Finance Committee of the American Association of 
      Immunologists and serves as a Deputy Editor for the Journal of 
      Immunology. Dr. Kronenberg was named a Roy and Robert Kroc 
      Distinguished Visiting Professor of Immunology and Medicine by the 
      University of California, Davis in 2000, and was a Borroughs Wellcome 
      Fund Visiting Professor at Harvard University in 2002.
    
    
      Dr. Liang Qiao, Chairman and CEO of Bio-Bridge Science, commented, “We 
      are very pleased to work with Dr. Kronenberg. His expertise and 
      experience in immunology is widely respected and we look forward to 
      receiving his valuable advice and recommendations.”
    
    
      Dr. Kronenberg joins Dr. Katherine Knight, Chairperson and Professor of 
      Microbiology and Immunology at Loyola University Chicago and past 
      President of the American Association of Immunologists, on the 
      Scientific Advisory Board of Bio-Bridge Science.
    
    
      This press release contains forward-looking statements. Forward-looking 
      statements include statements concerning plans, objectives, goals, 
      strategies, future events or performance, and underlying assumptions and 
      other statements that are other than statements of historical facts. 
      These statements are subject to uncertainties and risks including, but 
      not limited to, product and service demand and acceptance, changes in 
      technology, economic conditions, the impact of competition and pricing, 
      government regulation, and other risks defined in this document and in 
      statements filed from time to time with the Securities and Exchange 
      Commission. All such forward-looking statements, whether written or 
      oral, and whether made by or on behalf of the company, are expressly 
      qualified by these cautionary statements and any other cautionary 
      statements which may accompany the forward-looking statements. In 
      addition, the company disclaims any obligation to update any 
      forward-looking statements to reflect events or circumstances after the 
      date hereof. Please refer to the Company's SEC filings for additional 
      information.